Efficacy and safety of tralokinumab plus topical corticosteroids in patients with severe atopic dermatitis and prior history of dupilumab treatment: a post hoc subgroup analysis from ECZTRA 7 trial

Main Article Content

Jan Gutermuth
Andrew Pink
Margitta Worm
Lise Soldbro
Thomas Mark
Joshua Corriveau
Christian Bjeeregard Oland
Stephan Weidinger


tralokinumab, atopic dermatitis, efficacy, safety, dupilumab




1. Weidinger S, Novak N. Lancet. 2016;387:1109–22;

2. Eckert L, et al. J Am Acad Dermatol. 2017;77:274–9.e273;

3. Silverberg JI, et al. Ann
Allergy Asthma Immunol. 2018;121:340–7;

4. Dalgard FJ, et al. J Invest Dermatol. 2015;135:984–91;

5. Bieber T. Allergy. 2020;75:54–62;

6. Tsoi LC, et al. J Invest Dermatol. 2019;139:1480–9;

7. Popovic B, et al. J Mol Biol. 2017;429:208–19;

8. Simpson et al. Safety of specifically targeting interleukin 13 with tralokinumab in adult patients with moderate-to-severe atopic dermatitis: pooled analysis of five randomised, doubleblind, placebo-controlled Phase 3 and Phase 2 trials. Poster presented at: 29th EADV Congress; 29-31 October 2020; Virtual.

Similar Articles

You may also start an advanced similarity search for this article.

Most read articles by the same author(s)

1 2 3 > >>